drugset / Trial / NCT05678335
Tacrolimus for Thrombocytopenia in SS
RandomizedParallel-groupOpen-labelTreatment
Summary
This 12-week randomized, open-label study evaluates the efficacy and safety of Tacrolimus for Sjogren's syndrome patients with thrombocytopenia.
Timeline
- Start
- 2023-02
- Primary completion
- 2023-12
- Completion
- 2024-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Hydroxychloroquine | Small molecule | 200 mg | Oral |
| Subject | Tacrolimus | Small molecule | 1 mg | Oral |
| Subject | Tacrolimus | Small molecule | 2 mg | Oral |